JP2011519574A - 細胞ベースの治療に関連する材料および方法 - Google Patents
細胞ベースの治療に関連する材料および方法 Download PDFInfo
- Publication number
- JP2011519574A JP2011519574A JP2011507987A JP2011507987A JP2011519574A JP 2011519574 A JP2011519574 A JP 2011519574A JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011507987 A JP2011507987 A JP 2011507987A JP 2011519574 A JP2011519574 A JP 2011519574A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell population
- positive
- tissue
- adult
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 70
- 238000002560 therapeutic procedure Methods 0.000 title description 7
- 239000000463 material Substances 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 261
- 210000000130 stem cell Anatomy 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 210000004504 adult stem cell Anatomy 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000007850 degeneration Effects 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 5
- 210000004185 liver Anatomy 0.000 claims description 48
- 210000001519 tissue Anatomy 0.000 claims description 48
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 claims description 28
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 22
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 18
- 102000008730 Nestin Human genes 0.000 claims description 18
- 108010088225 Nestin Proteins 0.000 claims description 18
- 210000005055 nestin Anatomy 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 102100032912 CD44 antigen Human genes 0.000 claims description 16
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 16
- 102100032412 Basigin Human genes 0.000 claims description 15
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 15
- 210000003494 hepatocyte Anatomy 0.000 claims description 15
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 14
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 14
- 210000000496 pancreas Anatomy 0.000 claims description 13
- 239000002458 cell surface marker Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 239000002356 single layer Substances 0.000 claims description 10
- 210000000277 pancreatic duct Anatomy 0.000 claims description 8
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 7
- 210000002919 epithelial cell Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000000120 cytopathologic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 108010082117 matrigel Proteins 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 239000002771 cell marker Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 description 65
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 230000014509 gene expression Effects 0.000 description 36
- 102000004877 Insulin Human genes 0.000 description 32
- 108090001061 Insulin Proteins 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- 239000002609 medium Substances 0.000 description 23
- 102100027211 Albumin Human genes 0.000 description 19
- 108010088751 Albumins Proteins 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 13
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 13
- 102100038081 Signal transducer CD24 Human genes 0.000 description 13
- 108010065472 Vimentin Proteins 0.000 description 13
- 102000013127 Vimentin Human genes 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 210000005048 vimentin Anatomy 0.000 description 13
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 11
- 210000001900 endoderm Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- -1 c-Met Proteins 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 102000051325 Glucagon Human genes 0.000 description 9
- 108060003199 Glucagon Proteins 0.000 description 9
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 9
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 9
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
- 229960004666 glucagon Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 8
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 8
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- 230000004660 morphological change Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 7
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000002304 esc Anatomy 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003716 mesoderm Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 4
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 4
- 108010066302 Keratin-19 Proteins 0.000 description 4
- 108010070507 Keratin-7 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 101150052863 THY1 gene Proteins 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 3
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 101150003286 gata4 gene Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 230000032014 pancreas induction Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 101100260565 Dictyostelium discoideum thyA gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 1
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000930457 Rattus norvegicus Albumin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000034149 carbohydrate storage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QVFWZNCVPCJQOP-UHFFFAOYSA-N chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000020619 endoderm development Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000026917 foregut morphogenesis Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150068774 thyX gene Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5209808P | 2008-05-09 | 2008-05-09 | |
| US61/052,098 | 2008-05-09 | ||
| PCT/GB2009/001149 WO2009136168A1 (en) | 2008-05-09 | 2009-05-08 | Materials and methods relating to cell based therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519574A true JP2011519574A (ja) | 2011-07-14 |
| JP2011519574A5 JP2011519574A5 (enExample) | 2012-06-21 |
Family
ID=40935531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507987A Pending JP2011519574A (ja) | 2008-05-09 | 2009-05-08 | 細胞ベースの治療に関連する材料および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20110158961A1 (enExample) |
| EP (1) | EP2283115A1 (enExample) |
| JP (1) | JP2011519574A (enExample) |
| CN (1) | CN102083964B (enExample) |
| WO (1) | WO2009136168A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522281A (ja) * | 2012-06-26 | 2015-08-06 | セラクシス，インコーポレーテッド | インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 |
| WO2018034023A1 (ja) * | 2016-08-18 | 2018-02-22 | 北海道公立大学法人札幌医科大学 | 寿命延長剤 |
| JP2022501045A (ja) * | 2018-09-21 | 2022-01-06 | アプステム セラピューティクス、インコーポレイテッド | ヒト多能性成人幹細胞 |
| US12203096B2 (en) | 2017-04-04 | 2025-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation, expansion, and uses of adult pluripotent stem cells |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537538A (ja) | 2010-08-13 | 2013-10-03 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー | 微小水泡および関連するマイクロｒｎａの治療用途 |
| WO2014091373A1 (en) | 2012-12-11 | 2014-06-19 | The University Court Of The University Of Glasgow | Cellular and molecular therapies for peripheral vascular disease |
| US11920155B2 (en) | 2016-03-30 | 2024-03-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
| US20190085296A1 (en) * | 2017-09-20 | 2019-03-21 | Sergio Mora | Method of expansion of human pancreas progenitor cells from stem cells using feeder-conditioned media |
| US12365872B2 (en) | 2018-09-19 | 2025-07-22 | Lineage Cell Therapeutics, Inc. | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| US11603518B2 (en) | 2019-01-23 | 2023-03-14 | Asterias Biotherapeutics, Inc. | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
| CN113710285A (zh) * | 2019-03-26 | 2021-11-26 | 宾州研究基金会 | 用于治疗癌症的方法和材料 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006120476A1 (en) * | 2005-05-13 | 2006-11-16 | The University Court Of The University Of Glasgow | Materials and methods relating to cell based therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020012653A1 (en) * | 1997-12-19 | 2002-01-31 | Kevin Pang | Bile duct progenitor cells and methods of use |
| US6878543B1 (en) * | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
| KR100973424B1 (ko) * | 2001-09-20 | 2010-08-03 | 안티캔서, 인코포레이티드 | 네스틴 발현 모낭 줄기 세포 |
| US20040029269A1 (en) * | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
-
2009
- 2009-05-08 JP JP2011507987A patent/JP2011519574A/ja active Pending
- 2009-05-08 US US12/991,878 patent/US20110158961A1/en not_active Abandoned
- 2009-05-08 CN CN2009801260075A patent/CN102083964B/zh not_active Expired - Fee Related
- 2009-05-08 WO PCT/GB2009/001149 patent/WO2009136168A1/en not_active Ceased
- 2009-05-08 EP EP09742364A patent/EP2283115A1/en not_active Withdrawn
-
2013
- 2013-05-21 US US13/898,625 patent/US20130280219A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006120476A1 (en) * | 2005-05-13 | 2006-11-16 | The University Court Of The University Of Glasgow | Materials and methods relating to cell based therapies |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013057430; ＳＴＥＶＥＮＳＯＮ，Ｋ．Ｓ． ｅｔ ａｌ．: 'Ｉｓｏｌａｔｉｏｎ， ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ， ａｎｄ ｄｉｆｆｅｒｅｎｔｉａｔｉｏｎ ｏｆ ｔｈｙ１．１-ｓｏｒｔｅｄ ｐａｎｃｒｅａｔｉｃ ａｄｕｌｔ ｐｒｏｇｅｎｉｔｏｒ ｃｅｌｌ ｐ' Ｓｔｅｍ Ｃｅｌｌｓ Ｄｅｖ． Ｖｏｌ．１８， Ｎｏ．１０, 200912, ｐｐ．１３８９-９８ * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522281A (ja) * | 2012-06-26 | 2015-08-06 | セラクシス，インコーポレーテッド | インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 |
| JP2018193394A (ja) * | 2012-06-26 | 2018-12-06 | セラクシス，インコーポレーテッド | インスリン依存性糖尿病の治療に有用な幹細胞と膵臓細胞 |
| WO2018034023A1 (ja) * | 2016-08-18 | 2018-02-22 | 北海道公立大学法人札幌医科大学 | 寿命延長剤 |
| JPWO2018034023A1 (ja) * | 2016-08-18 | 2019-06-13 | 北海道公立大学法人 札幌医科大学 | 寿命延長剤 |
| US12203096B2 (en) | 2017-04-04 | 2025-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation, expansion, and uses of adult pluripotent stem cells |
| JP2022501045A (ja) * | 2018-09-21 | 2022-01-06 | アプステム セラピューティクス、インコーポレイテッド | ヒト多能性成人幹細胞 |
| JP7329265B2 (ja) | 2018-09-21 | 2023-08-18 | アプステム セラピューティクス、インコーポレイテッド | ヒト多能性成人幹細胞 |
| US11845956B2 (en) | 2018-09-21 | 2023-12-19 | APstem Therapeutics, Inc. | Human pluripotent adult stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1157814A1 (en) | 2012-07-06 |
| US20110158961A1 (en) | 2011-06-30 |
| WO2009136168A1 (en) | 2009-11-12 |
| CN102083964B (zh) | 2013-06-12 |
| CN102083964A (zh) | 2011-06-01 |
| EP2283115A1 (en) | 2011-02-16 |
| US20130280219A1 (en) | 2013-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519574A (ja) | 細胞ベースの治療に関連する材料および方法 | |
| JP2011519574A5 (enExample) | ||
| Passier et al. | Origin and use of embryonic and adult stem cells in differentiation and tissue repair | |
| JP4146802B2 (ja) | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 | |
| Dabeva et al. | Hepatic stem cells and liver repopulation | |
| CA2867953C (en) | Regulating stem cells | |
| CN112891374B (zh) | 治疗中风的影响的方法 | |
| JP2014000096A (ja) | ヒト胚性幹細胞の造血分化 | |
| JPWO2008153179A1 (ja) | 脂肪組織由来多系統前駆細胞 | |
| JP6860921B2 (ja) | 血液細胞を用いた組織・臓器の作製方法 | |
| WO2012133948A1 (ja) | 生体組織から単離できるssea-3陽性の多能性幹細胞を含む他家移植用細胞治療用組成物 | |
| US20090274663A1 (en) | Materials and Methods Relating to Cell Based Therapies | |
| Kao et al. | Comparisons of differentiation potential in human mesenchymal stem cells from Wharton’s jelly, bone marrow, and pancreatic tissues | |
| JPWO2004101775A1 (ja) | 新規な成体組織由来の幹細胞およびその用途 | |
| WO2004083414A1 (ja) | 単球由来多能性細胞ｍｏｍｃ | |
| CN113573720A (zh) | 提高视力的方法 | |
| Moshrefi et al. | Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat | |
| Watanabe et al. | Differentiation of a hepatic phenotype after heterotropic transplantation of heart, kidney, brain, and skin tissues into liver in F344 rats | |
| Rios et al. | Stem cells and their contribution to tissue repair | |
| HK1157814B (en) | Materials and methods relating to cell based therapies | |
| YOUNG | Isolation and characterization of human fetal liver progenitor stem cells | |
| Yeung | Mesenchymal Stem Cells In Islet Transplantion | |
| Wong | Bone Marrow Stem Cell-mediated Airway Epithelial Regeneration | |
| Blastocysts | Perspectives: Plasticity of Stem Cells | |
| IL193947A (en) | Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120425 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140318 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140418 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141003 |